Skip to main content

Table 5 Changes in clinical laboratory data during the observation period

From: Clinical advantage and tolerability of ibandronate in hemodialysis patients: a retrospective study

  Baseline End of study P*
Hemoglobin (g/dL) 10.2 ± 1.3 10.1 ± 0.8 0.75
Hematocrit (%) 31.7 ± 3.9 31.2 ± 2.5 0.66
Platelet count (× 104 cells/mm3) 16.2 ± 5.7 16.1 ± 5.3 0.86
Blood urea nitrogen (mg/dL) 57.0 ± 13.3 60.7 ± 11.8 0.31
Serum creatinine (mg/dL) 9.6 ± 2.2 10.0 ± 2.5 0.55
Serum sodium (mEq/L) 137.7 ± 2.2 137.0 ± 2.4 0.09
Serum potassium (mEq/L) 4.8 ± 0.6 5.2 ± 0.9 0.08
Serum chloride (mEq/L) 107.1 ± 2.4 107.0 ± 2.0 0.93
Serum calcium (mEq/L) 8.8 ± 0.6 8.8 ± 0.7 0.84
Serum inorganic phosphorus (mEq/L) 5.2 ± 1.1 5.2 ± 1.5 0.99
Aspartate transaminase (U/L) 11.8 ± 4.1 9.4 ± 3.0 0.03
Alanine aminotransferase (U/L) 8.6 ± 2.8 6.7 ± 2.6 < 0.01
Alkaline phosphatase (U/L) 278.8 ± 102.1 265.2 ± 111.6 0.34
Lactate dehydrogenase (U/L) 176.1 ± 24.1 170.6 ± 35.4 0.41
Total protein (g/dL) 6.2 ± 0.5 6.2 ± 0.6 0.95
Intact PTH (pg/mL) 284.8 ± 224.4 306.1 ± 355.1 0.71
  1. Values represent mean ± standard deviation
  2. PTH parathyroid hormone
  3. *Paired t test (P < 0.05)